PA8546101A1 - Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas - Google Patents

Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas

Info

Publication number
PA8546101A1
PA8546101A1 PA20028546101A PA8546101A PA8546101A1 PA 8546101 A1 PA8546101 A1 PA 8546101A1 PA 20028546101 A PA20028546101 A PA 20028546101A PA 8546101 A PA8546101 A PA 8546101A PA 8546101 A1 PA8546101 A1 PA 8546101A1
Authority
PA
Panama
Prior art keywords
polinergic
agent
treatment
combination
airways
Prior art date
Application number
PA20028546101A
Other languages
English (en)
Inventor
Michael Yeadon
Roisin A Armstrong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8546101A1 publication Critical patent/PA8546101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMBINACION DE UN AGONISTA SELECTIVO DEL RECEPTOR A2A DE ADENOSINA Y UN AGENTE ANTICOLINERGICO PARA LA ADMINISTRACION SIMULTANEA, CONSECUTIVA O SEPARADA POR VIA DE INHALACION EN EL TRATAMIENTO DE UNA ENFERMEDAD OBSTRUCTIVA DE LAS VIAS AEREAS U OTRA ENFERMEDAD INFLAMATORIA, CON LA CONDICION DE QUE EL AGENTE ANTICOLINERGICO NO SEA UNA SAL DE TIOTROPIO.
PA20028546101A 2001-05-25 2002-05-24 Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas PA8546101A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
PA8546101A1 true PA8546101A1 (es) 2003-12-10

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028546101A PA8546101A1 (es) 2001-05-25 2002-05-24 Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas

Country Status (22)

Country Link
US (1) US20040171576A1 (es)
EP (1) EP1395287A1 (es)
KR (1) KR20030097901A (es)
CN (1) CN1535161A (es)
AP (1) AP2003002911A0 (es)
BG (1) BG108383A (es)
BR (1) BR0209986A (es)
CA (1) CA2448086A1 (es)
CO (1) CO5540324A2 (es)
CZ (1) CZ20033126A3 (es)
EE (1) EE200300586A (es)
HU (1) HUP0400029A2 (es)
IL (1) IL158774A0 (es)
MA (1) MA27028A1 (es)
MX (1) MXPA03010787A (es)
NO (1) NO20035202D0 (es)
OA (1) OA12609A (es)
PA (1) PA8546101A1 (es)
PL (1) PL366899A1 (es)
SK (1) SK14302003A3 (es)
SV (1) SV2003001055A (es)
WO (1) WO2002096462A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
US20100041662A1 (en) 2006-10-30 2010-02-18 Sandrine Ferrand Heterocyclic compounds as antiinflammatory agents
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CA2771532C (en) 2009-08-17 2021-03-23 Intellikine, Inc. Heterocyclic compounds and uses thereof
AU2010284972A1 (en) 2009-08-20 2012-03-08 Novartis Ag Heterocyclic oxime compounds
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
WO2000023457A1 (en) * 1998-10-16 2000-04-27 Pfizer Limited Adenine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
MXPA03010787A (es) 2004-03-02
WO2002096462A1 (en) 2002-12-05
SK14302003A3 (sk) 2004-08-03
HUP0400029A2 (hu) 2004-04-28
CZ20033126A3 (cs) 2004-09-15
CO5540324A2 (es) 2005-07-29
SV2003001055A (es) 2003-11-14
EE200300586A (et) 2004-04-15
CN1535161A (zh) 2004-10-06
PL366899A1 (en) 2005-02-07
CA2448086A1 (en) 2002-12-05
IL158774A0 (en) 2004-05-12
MA27028A1 (fr) 2004-12-20
AP2003002911A0 (en) 2003-12-31
EP1395287A1 (en) 2004-03-10
NO20035202D0 (no) 2003-11-24
BG108383A (bg) 2004-08-31
US20040171576A1 (en) 2004-09-02
OA12609A (en) 2006-06-09
BR0209986A (pt) 2004-04-06
KR20030097901A (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
PA8546101A1 (es) Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
AR054139A1 (es) Formulacion modificada y de liberacion inmediata de esferas de memantina
PA8502901A1 (es) Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
BR0317573A (pt) Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
HK1064607A1 (en) Use of sucralfate for the preparation of medicament of cervical erosion treatment
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
SV2004001426A (es) Combinacion farmaceutica ref.pcs22049
PA8560401A1 (es) Combinacion farmaceutica
CR7162A (es) Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
PA8560601A1 (es) Combinacion farmaceutica
HN2002000128A (es) Un agonista de a2a en combinación con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas.
UY27308A1 (es) Un agonista de a2a en combinación con un agente anticolinérgico para el tratamiento de enfermedades obstructivas de las vias aéreas
CU23203A1 (es) Formulaciones que contienen agentes de accion trombolitica para su administracion por via rectal
DOP2002000514A (es) Combinacion farmaceutica.
BR0115413A (pt) Tratamento de ejaculação precoce
SV2003001056A (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermadades obstructivas de vias respiratorias
BRPI0409127A (pt) combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
EA200301153A1 (ru) Комбинация агониста рецептора аденозина a2a и антихолинергического агента для лечения обструктивных заболеваний дыхательных путей
DOP2002000523A (es) Combinacion farmaceutica.